Mirapexin
Authorised
This medicine is authorised for use in the European Union
pramipexole
MedicineHumanAuthorised
Overview
This is a summary of the European public assessment report (EPAR) for Mirapexin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mirapexin.
Mirapexin is a medicine that contains the active substance pramipexole. It is available as ‘immediate-release’ white tablets (round: 0.088, 0.7 and 1.1 mg; oval: 0.18 and 0.35 mg) and as ‘prolonged-release’ white tablets (round: 0.26 and 0.52 mg; oval: 1.05, 1.57, 2.1, 2.62 and 3.15 mg). Immediate-release tablets release the active substance immediately, and prolonged-release tablets release it slowly over a few hours.
Mirapexin is used to treat the symptoms of the following diseases:
- Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Mirapexin can be used either on its own or in combination with levodopa (another medicine for Parkinson’s disease), at any stage of disease including the later stages when levodopa starts becoming less effective;
- moderate to severe restless-legs syndrome, a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night. Mirapexin is used when a specific cause for the disorder cannot be identified.
The medicine can only be obtained with a prescription.
For Parkinson’s disease, the starting dose is either one 0.088-mg immediate-release tablet three times a day or one 0.26-mg prolonged-release tablet once a day. The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated. The maximum daily dose is three 1.1-mg immediate-release tablets or one 3.15-mg prolonged-release tablet. Patients can be switched from the immediate- to the prolonged-release tablets overnight, but the dose might need to be adjusted depending on the patient’s response. Mirapexin must be given less often in patients who have problems with their kidneys. If treatment is stopped for any reason, the dose should be decreased gradually.
For restless-legs syndrome, Mirapexin immediate-release tablets should be taken once a day, two to three hours before going to bed. The recommended starting dose is 0.088 mg, but, if needed, this can be increased every four to seven days to reduce symptoms further, to a maximum of 0.54 mg. The patient’s response and the need for further treatment should be evaluated after three months. The prolonged-release tablets are not suitable for restless-legs syndrome.
Mirapexin tablets should be swallowed with water. The prolonged-release tablets must not be chewed, divided or crushed, and should be taken around the same time every day. For more information, see the package leaflet.
The active substance in Mirapexin, pramipexole, is a dopamine agonist (a substance that imitates the action of dopamine). Dopamine is a messenger substance in the parts of the brain that control movement and coordination. In patients with Parkinson’s disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’s disease, such as shaking, stiffness and slowness of movement.
The way pramipexole works in restless legs syndrome is not fully understood. The syndrome is thought to be caused by problems in the way dopamine works in the brain, which may be corrected by pramipexole.
In Parkinson’s disease, Mirapexin immediate-release tablets have been studied in five main studies. Four studies compared Mirapexin with placebo (a dummy treatment): one study in 360 patients with advanced disease who were already taking levodopa that was starting to become less effective, and three studies in a total of 886 patients with early disease who were not receiving levodopa. The main measure of effectiveness was the change in the severity of Parkinson’s disease. The fifth study compared Mirapexin with levodopa in 300 patients with early disease, and measured the number of patients who had movement symptoms.
To support the use of the prolonged-release tablets, the company presented the results of studies showing that the immediate- and prolonged-release tablets produced the same levels of the active substance in the body. It also presented studies comparing the two tablets in early and advanced Parkinson’s disease, and looking at switching patients from immediate- to prolonged-release tablets. In restless-legs syndrome, Mirapexin immediate-release tablets have been studied in two main studies.
The first compared Mirapexin with placebo over 12 weeks in 344 patients and measured the improvement in symptoms. The second included 150 patients who took Mirapexin for six months, and compared the effects of remaining on Mirapexin with switching to placebo. The main measure of effectiveness was the time until symptoms got worse.
In the study of patients with advanced Parkinson’s disease, patients taking Mirapexin immediate-release tablets had larger improvements after 24 weeks of steady-dose treatment than those taking placebo. Similar results were seen in the first three studies of early Parkinson’s disease, with greater improvements after four or 24 weeks. Mirapexin was also more effective than levodopa at improving movement symptoms in early disease.
The additional studies showed that the prolonged-release tablets were as effective as the immediate-release tablets in treating Parkinson’s disease. They also showed that patients can be safely switched from immediate- to prolonged-release tablets, although dose adjustments were needed in a small number of patients.
In restless-legs syndrome, Mirapexin immediate-release tablets were more effective than placebo at reducing symptoms over 12 weeks, but the difference between placebo and Mirapexin was greatest after four weeks before getting smaller. The results of the second study were insufficient to prove the long-term effectiveness of Mirapexin.
The most common side effect with Mirapexin (seen in more than 1 patient in 10) is nausea (feeling sick). In patients with Parkinson’s disease, the following side effects are also seen in more than 1 patient in 10: dizziness, dyskinesia (difficulty controlling movement) and somnolence (sleepiness). For the full list of all side effects reported with Mirapexin, see the package leaflet.
Mirapexin should not be used in people who may be hypersensitive (allergic) to pramipexole or any of the other ingredients.
The CHMP decided that Mirapexin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the European Union for Mirapexin on 23 February 1998. The marketing-authorisation holder is Boehringer Ingelheim International GmbH. The marketing authorisation is valid for an unlimited period.
For more information about treatment with Mirapexin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Product information
Latest procedure affecting product information: H/C/WS2626
14/03/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Mirapexin
- Active substance
- pramipexole dihydrochloride monohydrate
- International non-proprietary name (INN) or common name
- pramipexole
- Therapeutic area (MeSH)
- Restless Legs Syndrome
- Parkinson Disease
- Anatomical therapeutic chemical (ATC) code
- N04BC05
Pharmacotherapeutic group
Anti-Parkinson drugsTherapeutic indication
Mirapexin is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).
Mirapexin is indicated for symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in dosages up to 0.54 mg of base (0.75 mg of salt).
Topics
This page was last updated on